6.02
0.00
(0.00%)
May 20 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 6.01 - 6.17 |
| 52 week | 3.10 - 7.73 |
| Open | 6.05 |
| Vol / Avg. | 0.00/840,197.00 |
| Mkt cap | 557.70M |
| P/E | - |
| Div/yield | - |
| EPS | -1.31 |
| Shares | 92.64M |
| Beta | 1.94 |
| Inst. own | 89% |
Events
Aug 7, 2013
Q2 2013 Orexigen Therapeutics, Inc. Earnings Release
Jun 5, 2013
Orexigen Therapeutics, Inc. Annual Shareholder Meeting
- 1:00PM EDT -
May 22, 2013
Orexigen Therapeutics, Inc. at UBS Global Healthcare Conference
- 11:00AM EDT -
May 15, 2013
Orexigen Therapeutics, Inc. at Bank of America Merrill Lynch Health Care Conference -
May 10, 2013
Q1 2013 Orexigen Therapeutics, Inc. Earnings Release
May 8, 2013
Q1 2013 Orexigen Therapeutics, Inc. Earnings Conference Call -
Mar 13, 2013
Q4 2012 Orexigen Therapeutics, Inc. Earnings Conference Call -
Mar 8, 2013
Q4 2012 Orexigen Therapeutics, Inc. Earnings Release
Mar 4, 2013
Orexigen Therapeutics, Inc. at Cowen Health Care Conference -
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -2259.98% | -2628.18% |
| Operating margin | -2263.48% | -2632.41% |
| EBITD margin | - | -2623.28% |
| Return on average assets | -60.72% | -62.38% |
| Return on average equity | -115.88% | -102.86% |
| Employees | 41 | - |
| Carbon Disclosure Rating | - | - |
Address
Suite 200, 3344 N. Torrey Pines Court
LA JOLLA, CA 92037
United States - Map
+1-858-8758600 (Phone)
+1-858-8758650 (Fax)
LA JOLLA, CA 92037
United States - Map
+1-858-8758600 (Phone)
+1-858-8758650 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Orexigen Therapeutics, Inc. develops drug treatments for obesity and related disorders. Orexigen Therapeutics, Inc. develops and commercializes combinations of currently available drugs that are designed to achieve and sustain weight loss by enhancing satiety, diminishing appetite, improving energy expenditure and minimizing the body's efforts to compensate for weight loss.
Officers and directors
| Eckard Weber M.D. | Independent Chairman of the Board | |
| Michael A. Narachi | President, Chief Executive Officer, Director | |
| Joseph P. Hagan | Acting Chief Financial Officer, Treasurer, Chief Business Officer | |
| Heather D. Turner | Senior Vice President, General Counsel, Secretary | |
| Preston Klassen M.D., M.H.S. | Head of Global Contrave Program, Senior Vice President - Product Development | |
| Dawn Viveash M.D. | Senior Vice President - Regulatory Affairs | |
| Mark D. Booth | Chief Commercial Officer | |
| Louis C. Bock | Independent Director | |
| Wendy L. Dixon Ph.D. | Independent Director | |
| Brian H. Dovey | Independent Director |